SOURCES AND USES OF FUNDS AND PRO FORMA DEBT The table below sets forth the estimated sources and uses of funds in connection with certain transactions in connection with the Acquisition, assuming they occurred on

SOURCES AND USES OF FUNDS AND PRO FORMA DEBT

The table below sets forth the estimated sources and uses of funds in connection with certain transactions in connection with the Acquisition, assuming they occurred on September 30, 2019, and based on estimated amounts outstanding on that date. The actual amounts are subject to adjustments and may differ from the estimated amounts shown below depending on several factors, including, among others, the share price of our common stock, the number of Allergan ordinary shares and Allergan equity awards outstanding on the closing date of the Acquisition, accrued interest on our indebtedness subsequent to September 30, 2019, changes made to the sources of the contemplated financings and differences from our estimated fees and expenses. You should read the following together with the information included under the captions "Summary-The Acquisition," "Capitalization" and "Description of Other Indebtedness" included elsewhere in this offering memorandum and financial information incorporated by reference into this offering memorandum.

The following table sets forth certain metrics relating to our capitalization as of September 30, 2019 on a pro forma as adjusted basis to give effect to this offering and the Acquisition and the related transactions as if they had occurred on such date. You should read the data set forth in the table below in conjunction with "Use of Proceeds" and our consolidated financial statements and related notes and the unaudited pro forma condensed combined financial statements incorporated by reference in this offering memorandum. The pro forma as adjusted information set forth below may not reflect our cash, debt and capitalization in the future.